<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03542409</url>
  </required_header>
  <id_info>
    <org_study_id>HCI77238</org_study_id>
    <nct_id>NCT03542409</nct_id>
  </id_info>
  <brief_title>Safety and Feasibility of Preoperative and Intraoperative Image-Guided Resection of Gliomas</brief_title>
  <official_title>Assessment of Safety and Feasibility of Preoperative and Intraoperative Image-Guided Resection of Gliomas and Tumor Region-Specific Biomarker Correlation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the use of specialized magnetic resonance imaging (MRI) techniques
      including magnetic resonance (MR) perfusion and 2-hydroxyglutarate (2HG) spectroscopy in the
      surgical treatment of gliomas. Participants will undergo an MR perfusion scan or 2-HG
      spectroscopy prior to surgery and intra-operatively.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 6, 2017</start_date>
  <completion_date type="Anticipated">February 6, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 6, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraoperative Imaging Completion</measure>
    <time_frame>1 day</time_frame>
    <description>This is a feasibility study to see whether advanced imaging modalities can be used intraoperatively so the primary outcome is a yes/no regarding completion of imaging.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Patient Complications Following Tumor Resection</measure>
    <time_frame>1 year</time_frame>
    <description>Any surgical complications at post-op, hospital discharge, 1-month, 3-months, 6-months, and 1 year following surgery using the Common Terminology Criteria for Adverse Events (CTCAE)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Brain Tumor Adult</condition>
  <arm_group>
    <arm_group_label>Group A (contrast enhancing tumor)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group A patients will undergo standard tumor preoperative imaging and MR perfusion scan prior to surgical resection. Group A patients will undergo standard intraoperative imaging along with MR perfusion scan during surgical resection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B (non-enhancing tumor)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group B patients will undergo standard tumor preoperative imaging and 2HG spectroscopy scan prior to surgical resection. Group A patients will undergo standard intraoperative imaging along with 2HG spectroscopy scan during surgical resection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MR Perfusion Scan</intervention_name>
    <description>MR perfusion scan before and during surgery.</description>
    <arm_group_label>Group A (contrast enhancing tumor)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>2HG Spectroscopy Scan</intervention_name>
    <description>2HG spectroscopy scan before and during surgery.</description>
    <arm_group_label>Group B (non-enhancing tumor)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Suspected glioma (grade II, III, or IV)

          -  Preoperative MR perfusion (enhancing tumors)

          -  Preoperative MR 2-HG spectroscopy (nonenhancing tumors)Patient indicated for surgical
             resection, standard radiation, and standard chemotherapy as a standard of care

          -  Karnofsky performance status ≥ 60

          -  Life expectancy &gt; 12 weeks

          -  Ability to comply with study and follow-up procedures

        Exclusion Criteria:

          -  Prior diagnosis of intracranial glioma

          -  Other malignancy with expected need for systemic therapy within 3 years

          -  Inability to have 6000 grays of radiation to the brain

          -  Need for urgent palliative intervention for primary disease (e.g., impending
             herniation)

          -  Evidence of bleeding diathesis or coagulopathy

          -  History of intracerebral abscess within 6 months prior to Day 0

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to Day 0, anticipation of need for major surgical procedure during the course of
             the study

          -  Pregnant or nursing females

          -  Subjects unable to undergo an MRI with contrast
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Amiee Maxwell</last_name>
    <phone>801-587-4720</phone>
    <email>amiee.maxwell@hci.utah.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amiee M Maxwell</last_name>
      <phone>801-587-4720</phone>
      <email>amiee.maxwell@hci.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Karsy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 1, 2018</study_first_submitted>
  <study_first_submitted_qc>May 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2018</study_first_posted>
  <last_update_submitted>January 17, 2020</last_update_submitted>
  <last_update_submitted_qc>January 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

